However, as no extra dose can be given without additional toxicity, they postulate preventing unplanned treatment gaps and not compensating for them by dose escalation should be implemented whenever possible.
The full planned dose could be given without delays in 66 of 70 patients FE120C is well tolerated and is highly effective as up-front chemotherapy in relatively young patients with high-risk breast cancer, with a 90% (CI 74-9874-98%nical objective response rate.
High-dose pemetrexed can be given without significant increase in serious toxicities, but this does not seem to increase efficacy (Hanna et al, 2006b; Gronberg et al, 2008; Socinski et al, 2008).
With respect to resuscitation outcomes, in group II (three doses of adrenaline first, followed by vasopressin; 113 patients with initial VF/VT rhythm) 29 patients were resuscitated after adrenaline only (29/113 [26%]) and 11 patients were resuscitated after vasopressin was given, without additional doses of adrenaline (11/31 [36%]).
Here, 60 women previously treated with platinum-based therapies received a median of four courses of docetaxel, 98% of which were given without the need for dose reduction.
Vaccine coverage was >90% for DTP3 (3 doses of diphtheria-tetanus-pertussis vaccines) and the doses were given without substantial delay.
Only one patient did not receive 100% of prescribed chemotherapy and radiotherapy doses because of toxicity, and the maximum protocol cisplatin and docetaxel doses (DL6) were given without achieving a MTD as predefined in the trial protocol, as also observed by Pasini et al (2005) with a similar backbone and doses, but with the addition of infusional 5-FU.
Twenty-five cycles (17 %) were given at a reduced dose, with 7 of these (5%%) being given without irinotecan in one patient.
27– 30 Combinations of the antioxidants have also been given without significant interactions or side effects described, although at lower doses.
